Nov 15, 2023
12:00-1:00 PM EST
Jiawei Zhou, PhDPharmacometrician, Pfizer Inc., New York, United States
Understand Tumor Response Heterogeneity in Colorectal Cancer: Share the similarities, celebrate the differences.
Oct 11, 2023
12:00-1:00 PM EDT
Mikael Boberg, PhDSenior Scientist, AstraZeneca R&D, Gothenburg, Sweden
PK/PD modelling of eflornithine: Assessment of an oral treatment for the fatal parasitic disease human African trypanosomiasis
Sep 13, 2023
12:00-1:00 PM EDT
Robin T.U. Haid, MScPhD Student, Bayer AG, Preclinical Development, Drug Metabolism and Pharmacokinetics, Preclinical Modeling and Simulation / ETH Zurich, Institute of Pharmaceutical Sciences, Biopharmacy
A Pharmacodynamic Model for the Assessment and Optimization of PROTACs
Aug 16, 2023
12:00-1:00 PM EDT
Sheena Sharma, PhDResearch Investigator, PBPK, Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Lawrenceville, NJ
Proteomics-Informed PBPK Modeling to Predict Systemic and Tissue Drug Concentrations in Rats
Jul 12, 2023
12:00-1:00 PM EDT
Dr. Marcus Rosenblatt, PhDPhysicist, Institute of Physics, University of Freiburg, Freiburg, Germany
Mechanistic insights into sensitization/desensitization of IFNα signaling and its effect on patient treatment strategies.
Jun 14, 2023
12:00-1:00 PM EDT
Jared Weddell, Ph.D.Senior Manager, Clinical Pharmacology and Exploratory Development, Astellas Pharma US, Northbrook, IL
A QSP model to understand clinical cytokine dynamics following bispecific dosing in solid tumors
May 17, 2023
9:00-10:00 AM PDT
Robert R. Bies, Pharm.D. Ph.D. FISoPProfessor of Pharmaceutical Sciences, Member Institute for Artificial Intelligence and Data Science, University at Buffalo, Buffalo NY
Leveraging machine learning strategies for nonlinear mixed effects model selection (using pyDarwin)
Apr 19, 2023
12:00-1:00 PM EDT
Rebecca Baillie, PhD, Christina Friedrich, PhD, Jake Nichols, PharmD, MBAPrincipal Scientist; Chief Engineer, Rosa & Co., San Carlos, CA; Director of Medical Affairs, US WorldMeds, Louisville, KY
Demonstrating Efficacy When Clinical Trials Are Impossible: QSP Modeling to Support a New Dose Application
Mar 15, 2023
9:00-10:00 AM PDT
Natalie Morris, BScUniversity of Bristol, Bristol, UK
Defining design rules for next-generation snakebite antivenoms
Feb 8, 2023
9:00-10:00 AM PST
Dr Dinko Rekic, PhD and Dr Jane Knöchel, PhDGlobal Product Leader – ticagrelor; Clinical Pharmacometrician, AstraZeneca, Gothenburg, Sweden
A case‐study of model‐informed drug development of a novel PCSK9 antisense oligonucleotide
Jan 18, 2023
9:00-10:00 AM PST
Vincent Lemaire, Ph.D.; Fei Hua, Ph.D.Distinguished Scientist Modeling and Simulation, Genentech, South San Francisco, CA; VP, Head of Modeling and Simulation Services, Aplied BioMath Concord, MA
From Cold to Hot: Perceptions of the Use and Impact of QSP in Immuno-oncology – A Survey of the Community and Stakeholders
Dec 12, 2022
The team is taking some time to spend with their families.
No Webinar for December
Nov 16, 2022
9:00-10:00 AM PST
Chuanpu Hu, PhDSenior Scientific Director and Fellow, Janssen R&D, LLC
Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervals
Oct 19, 2022
9:00-10:00 AM PDT
Wojciech Krzyzanski PhD, MAAssociate Professor, University at Buffalo
Pharmacodynamic age structured population model for cell trafficking
Sep 21, 2022
9:00-10:00 AM PDT
Philippe Moingeon PhD, MBAHead of Immuno-inflammation portfolio, Servier
AI-powered modeling approaches to support the development of new therapies for autoimmune diseases
Aug 17, 2022
9:00-10:00 AM PDT
Bill Brastow, Ph.D.Chief Technology Officer for Rosa Market Modeling
Injecting Reality into Commercial Due Diligence for In-Licensing, Partnering or Purchasing Pharmaceutical Assets in Development
Jul 13, 2022
1:00-2:00 PM PDT
• Christina Friedrich, PhD, Chief Engineer, Rosa & Co, San Carlos, CA
• Stephen Duffull, PhD, Professor, (1) Senior Scientific Advisor, Certara, (2) Otago Pharmacometrics Group, School of Pharmacy, University of Otago, Dunedin, New Zealand
• Theodore Rieger, PhD, Associate Research Fellow, Pfizer Inc, Cambridge, MA
• Kapil Gadkar, PhD, Staff Scientist, Denali Therapeutics, South San Francisco, CA
VPs... You got to know when to hold them, know when to remove them, know when to resample, know when to run.
Jun 15, 2022
9:00-10:00 AM PDT
Stefano Morotti, PhD.Assistant Professor at University of California Davis
Cross-species translation of drug-induced electrophysiological response in cardiac myocytes
May 25, 2022
9:00-10:00 AM PDT
Chuanpu Hu, PhD.Senior Scientific Director and Fellow at Janssen R&D, LLC
Analyzing Outcome Score Data
Apr 20, 2022
9:00-10:00 AM PDT
Joga GobburuProfessor, University of Maryland
Predictive Healthcare Analytics
Mar 16, 2022
9:00-10:00 AM PDT
Nick Holford, Emeritus ProfessorEmeritus Professor, University of Auckland, New Zealand
Concentration Guided Dosing
Feb 16, 2022
9:00-10:00 AM PST
Christina Friedrich, PhD; Jérémy HuardChief Engineer, PhysioPD, Rosa & Co, LLC; Senior Application Engineer, MathWorks
Using Machine Learning Surrogate Modeling for Faster QSP VP-Cohort Generation
Jan 20, 2022
9:00-10:00 AM
Check back soon for more webinars.
We are taking January off and will resume the webinars in February
Dec 8, 2021
9:00-10:00 AM PST
Dr. Dipak BaruaResearch Principal Scientist, Takeda Pharmaceutical Company Limited
A mechanistic model-based analysis of Fn14 - NF-Kappa B dysregulation in glioblastoma multiforme
Nov 17, 2021
9:00-10:00 AM PST
James Lu, PhDPrincipal AI Scientist, Genentech
Using Machine Intelligence in building PK/PD and Disease Progression Models
Oct 20, 2021
9:00-10:00 AM PDT
Dr Adam PalmerAssistant Professor of Pharmacology, UNC Chapel Hill
Models to understand and predict the clinical efficacy of combination cancer therapy
Sep 15, 2021
9:00-10:00 AM PDT
Yanguang (Carter) Cao, PhD.Assistant Professor | University of North Carolina at Chapel Hill
Probing antibody-target interactions in living systems
Jul 14, 2021
9:00-10:00 AM PDT
Tongli Zhang, PhDAssistant Professor, University of Cincinnati
Integrating Quantitative Systems Pharmacology and Machine learning, why bother?
Jun 9, 2021
12:00-1:00 PM EDT
Anastasios Siokis, PhDPostdoc in Translational Disease Modeling, Sanofi, Germany
An agent-based simulation platform studying the immunological synapse dynamics
May 12, 2021
12:00-1:00 PM EDT
Vincent Hurez, DVM, PhDSenior Scientist at Rosa & Co LLC
Predicting subjective or complex clinical outcomes in QSP models: challenges and approaches
Apr 14, 2021
12:00-1:00 PM EDT
Thorsten Lehr, PhDProfessor of Clinical Pharmacy, Saarland University
Cancelled
Mar 17, 2021
12:00-1:00 PM EDT
Amber Smith, PhD.Assistant Professor at The University of Tennessee Health Science Center
The Ravaging Respiratory Infection: Fighting Influenza Using Mechanistic Models
Feb 16, 2021
12:00-1:00 PM EST
Bill Brastow, PhDPrincipal and CTO Rosa Market Modeling
Out of the Lab - Into the Market: Modeling Physician Decision-Making Behavior Using Discrete Choice
Jan 20, 2021
12:00-1:00 PM EST
Luca Gerosa, PhDPostdoctoral Fellow, Laboratory of Systems Pharmacology, at Harvard Medical School
Building Kinetic Models with Complex Drug-Protein Interactions: application to the targeted inhibition of MAPK signaling in cancer
Dec 16, 2020
12:00-1:00 PM EST
Paul B. Watkins, M.D. FAASLD.Director, Institute for Drug Safety Sciences at the University of North Carolina in Chapel Hill
QST and the Transformation in Drug Safety Assessment
Nov 18, 2020
12:00-1:00 PM EST
Eric Sobie, PhDProfessor, Pharmacological Sciences at Icahn School of Medicine at Mount Sinai
Using QSP to predict cardiotoxicity caused by cancer drugs
Oct 14, 2020
12:00-1:00 PM EST
Katherine Kudrycki, PhDPrincipal Scientist at Rosa & Co. LLC
Do you need a life scientist for QSP modeling?
Sep 9, 2020
12:00-1:00 PM EDT
Stacey Tannenbaum, PhD, FISoPSenior Director, Pharmacometrics US Clinical Pharmacology and Exploratory Development, Astellas Pharma, Northbrook, IL
Making the 'Moster' of Your Poster
Jul 15, 2020
12:00-1:00 PM EDT
Dr. Jonathan E. AllenInformatics Thrust Leader, Biosecurity Center at ATOM Consortium and Lawrence Livermore National Laboratory
An Integrated Machine Learning Framework for Novel Small Molecule Drug Design
Jun 17, 2020
12:00-1:00 PM EDT
Sergio Iadevaia, PhDScientific Director QSP, Pharmacometrics and Data Analysis at Takeda
Development of a QSP Platform to Quantify Benefits of DAAO Inhibition in Schizophrenia
May 20, 2020
12:00-1:00 PM EDT
Paolo Denti, PhDAssociate Professor at the University of Cape Town
Of “clever” models and “dumb” spreadsheets”: what is more effective to drive policy change?
Apr 15, 2020
12:00-1:00 PM EDT
Iraj Hosseini, PhD and Justin Feigelman, PhDScientists at Genentech, Inc in South San Francisco
gQSPSim: a SimBiology®-based GUI app for standardized QSP model development and application
Mar 18, 2020
12:00-1:00 PM EDT
Dr. Bill BrastowPrincipal and Chief Technology Officer at Rosa Market Modeling
Driving Market Share for Healthcare Products by Integrating Market Modeling
Feb 19, 2020
12:00-1:00 PM EST
Rajanikanth (Raj) Madabushi, PhDTeam Lead, Guidance and Policy & CDER Point-of-Contact for the MIDD paired Meeting Pilot Program, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, USFDA
Mainstreaming MIDD: A Holistic and Integrative Approach
Jan 22, 2020
12:00-1:00 PM EST
Jeffrey R. Sachs, Ph.D.Senior Principal Scientist, Merck & Co., Inc. based in Kenilworth, NJ, USA, known as MSD outside Canada and USA
MIDD: Vaccine R&D Gets a Shot in the Arm from Pharmacometrics
Dec 11, 2019
12:00-1:00 PM EST
Sietse Braakman, PhDSimBiology Application Engineer at MathWorks
A general workflow for parameter estimation to help establish confidence in model predictions
Nov 14, 2019
12:00-1:00 PM EST
Dr. Britta GoebelHead of Translational Disease Modeling (Diabetes-CV & I&I) at Sanofi, Frankfurt
Quantitative Systems Pharmacology Modeling Support in Development of Novel Diabetes Treatments
Oct 24, 2019
12:00-1:00 PM EDT
Robert Bies, Pharm.D. Ph.DAssociate Professor of Pharmaceutical Sciences, Member Computational and Data Enabled Sciences Program at the University at Buffalo, NY
Hybrid Genetic Algorithm Approaches to Model Selection
Sep 18, 2019
12:00-1:00 PM EDT
James Yates, MMath, PhDPrincipal Scientist, AstraZeneca, Cambridge UK
Attack of the Clones: Understanding the kinetics of resistance to cancer treatment
Jul 18, 2019
12:00-1:00 PM EDT
Maria Trujillo PhDPrincipal Scientist, Merck and Co Inc, Kenilworth, NJ
Leveraging a Diabetes QSP Model to Drive Decisions in Target Identification and Validation for Proinsulin to Insulin Conversion Therapy
Jun 20, 2019
12:00-1:00 PM EDT
Loveleena Bansal, PhDScientific Leader, GSK Associate Fellow, at GSK, Collegeville PA
Modular development and application of platform QSP models to support a broad R&D portfolio: Examples from immuno-oncology and respiratory therapeutic areas
May 23, 2019
12:00-1:00 PM EDT
Vivaswath S. Ayyar, Ph.D.Adjunct Assistant Professor of Pharmaceutical Sciences, University at Buffalo, NY and PK/PD Scientist, Janssen BioTherapeutics, Spring House, PA
Expanding from Basic Towards Systems Pharmacodynamic Models for Methylprednisolone
Apr 17, 2019
12:00-1:00 PM EDT
Dr.-Ing. Markus RehbergScientist QSP at Sanofi-Aventis Deutschland GmbH
Systems Immunology Modeling: From Mechanistic Details to Clinical Outcomes in Rheumatoid Arthritis
Mar 14, 2019
12:00-1:00 PM EDT
Stephan Schmidt, B.Pharm, Ph.D., F.C.P.Associate Professor & Associate Director, Center for Pharmacometrics & Systems Pharmacology, University of Florida
Pharmacometrics, PBPK, QSP – What’s Next?
Feb 12, 2019
12:00-1:00 PM EST
Professor Ioannis (Yannis) P. AndroulakisRutgers University - Biomedical Engineering
Dynamic Models for Personalized QSP: How models can help us explore big data
Jan 23, 2019
12:00-1:00 PM EST
Chi-Chung Li, Ph.D., Senior Scientist, Clinical Pharmacology, and Iraj Hosseini, PhD. ScientistGenentech, Roche, South San Francisco.
Enhancing Phase I Clinical Decision Making Through the Use of Quantitative Systems Pharmacology Modeling: A Case Study of Mosunetuzumab in Relapsed/Refractory Non-Hodgkin’s Lymphoma
Dec 12, 2018
12:00-1:00 PM EST
Eric Sobie, PhD, Professor, Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
Combining mechanistic modeling with machine learning to predict cardiotoxicity and streamline drug development
Nov 14, 2018
12:00-1:00 PM EST
Theresa Yuraszeck, Associate Director, Quantitative Pharmacology, CSL Behring
Quantitative Approaches to Informing Clinical Decisions – Where does Systems Pharmacology Fit In?
Oct 24, 2018
1:00-2:00 PM EDT
Iraj Hosseini, PhD. Scientist at Genentech
The gPKPDsim Simbiology app
Sep 20, 2018
12:00-1:00 PM EDT
Prasad Dhurjati, PhD, Professor of Chemical & Bio-molecular Engineering, Joint appointment as Professor Biological Sciences and Professor of Mathematical Sciences, University of Delaware
System Level Modeling of the Human Gut Microbiome
Jul 18, 2018
1:00-2:00 PM EDT
Richard Gliklich, MD, Founder and CEO, OM1
Advancing Drug Development and Outcomes Research with Artificial Intelligence, Machine Learning, and Predictive Models
Jun 13, 2018
12:00-1:00 PM EDT
Aman Singh, PK-PD Scientist, Biologics Development Sciences, Janssen R&D
Towards Development of a Systems PK-PD Model to Characterize Bystander Effect of Antibody-Drug Conjugates (ADCs)
May 17, 2018
1:00-2:00 PM EDT
1) Lealem Mulugeta, Executive Committee Member of CPMS, Founder/Executive of InSilico Labs and Medalist Fitness.
2) Andrew Drach, Senior Research Fellow at University of Texas at Austin, Executive Committee Member of CPMS
Ten Simple Rules of Credible Practice of Modeling and Simulation in Healthcare: Application to Bone Remodeling and Heart Valve Modeling
Apr 25, 2018
12:00-1:00 PM EST
Christina Friedrich, PhD, Chief Engineer, and Mike Reed, PhD, Chief Scientist, Rosa & Co, CA
How to Ensure Your QSP Model is Useful – Illustrative Examples and Lessons Learned
Mar 14, 2018
12:00-1:00 PM EST
Richard A. Gray, PhD, Senior Research Biomedical Engineer, Food and Drug Administration, Silver Spring, MD
The Potential Impact of Physiological Computer Models in Medicine: Regulation and Considerations for Ensuring Patient Safety
Feb 14, 2018
12:00 PM-1:00 AM EST
Frank Gibbons, PhD
Principal Scientist, DMPK, IMED Oncology Biotech Unit
AstraZeneca
Pulling your model up by its bootstraps: evolving your way to QSP
Jan 24, 2018
4:00-5:00 PM EST
Chihiro Hasegawa, PhD, PK/PD Scientist, Ono Pharma, Japan, Otago Pharmacometrics Group, School of Pharmacy, University of Otago, New Zealand
Automated scale reduction of nonlinear QSP models with an example of a bone biology system
Dec 13, 2017
12:00 PM-1:00 AM EST
Konstantinos (Kostas) Biliouris, PhD
Principal Pharmacometrics Scientist
Novartis
Cambridge, MA, USA
Quantitative Modeling in Support of the Development of a Systemic Lupus Erythematosus Drug
Nov 16, 2017
12:00-1:00 PM EST
Nelleke Snelder
Senior Consultant
LAP&P Consultants BV
Leiden, The Netherlands
QSP modelling - at the heart of the action.
Oct 26, 2017
12:00-1:00 PM EDT
Sietse Braakman, PhD
MathWorks
Enabling QSP and PK/PD workflows using SimBiology and MATLAB: What’s New?
Sep 13, 2017
11:00 AM-12:00 PM EDT
Dr. Ryan Tasseff
Scientist
Procter and Gamble
Development of a multiscale skin barrier model for de novo, in silico prediction
Jul 19, 2017
12:00-1:00 PM EDT
Valeriu Damian, Director
Systems Modeling and Translational Biology
GlaxoSmithKline, King of Prussia, PA
QSP - What’s in it for me? Case study examples
Jun 14, 2017
12:00-1:00 PM EDT
Dr. Herbert Sauro, Associate Professor, Bioengineering, University of Washington
Approaches to Reproducibility in Systems and Physiological Modeling
Apr 19, 2017
12:00-1:00 PM EDT
Aman P. Singh, PhD Candidate
Department of Pharmaceutical Sciences,
University at Buffalo, Buffalo, NY
A PK-PD Modeling and Simulation Based Strategy for Clinical Translation of Antibody-Drug Conjugates: A case study with T-DM1
Mar 22, 2017
12:00-1:00 PM EDT
Dr. Michael Weis, Senior Engineer, PhysioPD™, Rosa & Co.
Considerations for adopting models for PhysioPD-style Research
Feb 23, 2017
12:00-1:00 PM EST
Stacey Tannenbaum, PhD, FISoP
Director: Pharmacokinetics, Modeling, and Simulation
Clinical Pharmacology & Exploratory Development
Astellas Pharma Global Development; Northbrook, IL
Pharmacometricians and Statisticians in Drug Development: Can’t We All Just Get Along?
Jan 18, 2017
12:00-1:00 PM EST
Natal van Riel, MSc, PhD Professor Computational Modelling
Associate Professor Systems Biology and Metabolic Disease
Eindhoven University of Technology, and Amsterdam Medical Center
Eindhoven, The Netherlands
Quantification of Variability and Uncertainty in Multi-Level Systems Pharmacology Models
Dec 14, 2016
12:00-1:00 PM EST
Ben-Fillippo Krippendorff, Ph.D.
Quantitative Systems Pharmacology, Pharmaceutical Sciences
Roche Pharma Research & Early Development
Roche Innovation Center Basel
Predicting Tissue Distribution and Clearance of Large Molecules to Improve Selectivity of Targeted Therapies
Nov 16, 2016
12:00-1:00 PM EST
Craig Thalhauser, Ph.D., Associate Director/Quantitative Clinical Pharmacology, Bristol-Myers Squibb, Princeton, NJ
Calibration, Validation, and Responder Analysis in a Virtual Population of Rheumatoid Arthritis Patients
Oct 19, 2016
Michael Bolger, Ph.D., Chief Scientist and Ted Grasela, Ph.D., President, Simulations Plus; Lancaster, CA
Applying QSAR and PBPK Modeling to Bridge Discovery and Assessment of Clinical Potential
Sep 14, 2016
Helen Moore, PhD, Associate Director, Quantitative Clinical Pharmacology, Bristol-Myers Squibb, Princeton, NJ
Mathematical Optimization of Combination Therapy Regimens
Jul 13, 2016
Christina Friedrich, PhD, Chief Engineer, Rosa & Co., San Carlos, CA and Fulden Buyukozturk, PhD, Technical Evangelist, MathWorks; Natick, MA
MATLAB and SimBiology facilitate QSP modeling and analysis to support drug development
Jun 15, 2016
Melissa Hallow, Ph.D., Assistant Professor, College Of Engineering And Department Of Epidemiology And Biostatistics, University of Georgia, Athens, GA
Application of Physiology - Disease-Drug Model of Kidney Disease
May 11, 2016
Jonathan Wagg, MD, PhD, Disease Therapeutic Area Modeling Leader – Oncology, Roche Pharmaceutical Research and Early Development
Optimizing Delivery of Cancer Vaccines: Short Peptides Insights from Disease Modelling
Apr 13, 2016
Oliver Ghobrial, Sr. Scientist III, Systems Pharmacology/DMPK/PKPD, AbbVie, Inc.
AbbVie Dermatology QSP Platform: Build Strategy and Applications in Psoriasis Drug Discovery and Clinical Development
Mar 16, 2016
Dr. Lourdes Cucurull-Sanchez, Senior Scientific Investigator; GlaxoSmithKline
Modelling Cytokine Receptors as Drug Targets – A Case Study
Dec 9, 2015
Stephen Duffull, PhD, Chair of Clinical Pharmacy, Otago Pharmacometrics Group, School of Pharmacy, University of Otago, Dunedin, New Zealand
Systems models–their use and simplification
Oct 14, 2015
Ananth Kadambi, Ph.D., Senior Vice President, PhysioPD™, Rosa & Co.
Differential applications of Quantitative Systems Pharmacology and traditional modeling approaches in pharmaceutical R&D
Sep 16, 2015
Satyaprakash Nayak (Satya), Pharmacometrician - Systems Biologist at Pfizer
Development of a Quantitative Systems Pharmacology Model of the Blood Coagulation Network & its Application to Clinical Programs
Jul 17, 2015
Peter L. Bonate, PhD, Senior Director, Astellas; Global Head - Pharmacokinetics, Modeling, and Simulation; Global Clinical Pharmacology & Exploratory Development
Modeler Tailor Listener Buy
Jun 17, 2015
Eric A. Sobie Ph.D., Associate Professor, Dept. of Pharmacology and Systems Therapeutics; Icahn School of Medicine at Mount Sinai, NYC, NY
Quantitative Cardiovascular Systems Pharmacology: Exploiting mathematical models to generate novel insight
May 13, 2015
Loveleena Bansal, PhD, Post-Doctoral Researcher, GlaxoSmithKline
A Quantitative Systems Pharmacology (QSP) Approach to Understand the Pathogenesis of Acne and Evaluate New Acne Therapies
Apr 16, 2015
Dr. Ioannis (Yannis) P. Androulakis, Professor, Rutgers University, Piscataway, NJ
Systems engineering meets Quantitative Systems Pharmacology: From low-level targets to engaging the host defenses
Mar 11, 2015
Samik Ghosh, PhD, The Systems Biology Institute, Tokyo, Japan
Garuda: Fly to the future of biology
Feb 11, 2015
Sandra Visser, Principal Scientist, Early Stage Quantitative Pharmacology & Pharmacometrics, Merck
Bringing Quantitative and Systems Pharmacology to Drug Discovery: Implementation, Impact, and Challenges
Jan 14, 2015
Dr. Richard Peck, Global Head Clinical Pharmacology, Pharmaceutical Research and Development (pRED), Roche Products Ltd
How can We Use Mechanism-based Receptor Models for Designing First in Human Studies?
Dec 17, 2014
Mike Reed, Chief Scientist, PhysioPD, Rosa & Co
Building and Using a Quantitative Systems Pharmacology Model: Overview and Case Study
Oct 22, 2014
Hugo Geerts Scientific Liaison Officer at In Silico Biosciences
Quantitative Systems Pharmacology in CNS Disorders Providing value for Pharmaceutical R&D in Neurology and Psychiatry
Sep 24, 2014
Dhaval Shah Assistant Professor at SUNY Buffalo
Evolution of the Platform PBPK Model for Monoclonal Antibodies Towards Pediatric Population
Jul 16, 2014
Marc Birtwistle, PhD; Asst Professor, Pharmacology and Systems Therapeutics, Icahn School of Medicine, Mount Sinai, NY
Noise and Signaling in Cancer Systems Pharmacology
Jun 13, 2014
Yu-Nien (Tom) Sun, Director, Quantitative Pharmacology Group; Pharmacokinetics & Drug Metabolism Department, Amgen, Inc.
Model-Based Drug Development for Oncology Therapeutics
May 14, 2014
Kapil Gadkar, Scientist at Genentech
A mechanistic systems pharmacology model for prediction of LDL cholesterol lowering by anti-PCSK9 in human dyslipidemia
Apr 17, 2014
C.J. Musante, Associate Research Fellow, Cardiovascular and Metabolic Diseases; Gianluca Nucci, Senior Director, Clinical Pharmacology, and Mark Peterson Director, Pharmacometrics, Pfizer Inc.
Quantitative Systems Pharmacology at Pfizer: A Paradigm Shift to Improve the Probability of Successful Proof of Concept Studies
Mar 19, 2014
Thierry Lave, Head DMPK and TOX Project Leader and Modeling and Simulation, F. Hoffmann-La Roche
Translational modeling in support of nonclinical safety assessments
Feb 27, 2014
Ron Beaver, PhD, Founder, Chairman, and CEO, Rosa & Co LLC
Systems Pharmacology: Science or Non-science? And so what?
Dec 11, 2013
Dr. Yanguang Cao, Research Assistant Professor, Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY
Applications of minimal PBPK models to small and large molecules
Nov 13, 2013
Kosmas Kretsos, Associate Director, Global Exploratory Development, UCB New Medicines
Differentiate or die: Preclinical and early clinical assessment of differentiation potential via modeling
Oct 16, 2013
Dr. Frank Bergmann, University of Heidelberg
Applying the Scientific Method to Simulation Experiments
Sep 24, 2013
Tarek Leil, Director, Bristol-Myers Squibb
A Bayesian Perspective on Estimation of Variability and Uncertainty in Mechanism-Based Models
Jul 18, 2013
Robert Leipold, Research Scientist, Evidera
Modeling in Healthcare Economic Evaluations
Jun 19, 2013
Dean Bottino, Head Modeling & Simulation Oncology at Roche Pharmaceuticals
Multi-scale modeling to optimize the antitumor effect of antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced therapies
May 15, 2013
Michael A. Eldon, Principal Scientific Fellow, VP, Clinical Pharmacology, Nektar Therapeutics
PK/PD Modeling and simulation: Applications in discovery through development
Apr 24, 2013
Christina Friedrich, Chief Engineer, Rosa and Co.
Learnings from the Field: The Rosa Physiological Model Qualification Method
Mar 13, 2013
David J. Klinke II, Ph.D, Associate Professor, Chemical Engineering; West Virginia University
In silico model-based inference: A contemporary approach for hypothesis testing in systems
Feb 19, 2013
Dr. Chee Ng, Assistant Professor at Children's Hospital of Philadelphia
Model-based Discovery/Development of Therapeutic Monoclonal Antibodies
Dec 11, 2012
Dhavalkumar Shah, Senior Scientist; Modeling & Simulation, Pharmacokinetics, Dynamics, and Metabolism; Pfizer
Bench to Bedside Translation of Antibody Drug Conjugates Using a Multiscale Mechanistic PK/PD Model: A Case Study with SGN-35
Nov 14, 2012
Arthur Lo, Senior Scientist; Theravance
Integration of in vitro data into a viral kinetics model to investigate rapid development of Hepatitis C resistance to therapy
Oct 17, 2012
Pratap Singh, Ph.D, Senior Principal Scientist, Pfizer
Role of Myostatin in Muscle Growth: Key Learnings From PK/PD Modeling Analysis
Sep 19, 2012
Malcolm Rowland, PhD, Professor Emeritus, University of Manchester
Addressing drug development questions with physiologically based pharmacokinetics
Jul 20, 2012
Dr. Valeriu Damian-Iordache, Director Pharmacokinetics and Translational Biology, GlaxoSmithKline
Physiological based modeling for ocular drug delivery
Jun 19, 2012
Dr. Scott Q Siler, Lead DILI-sim Consultant
The DILIsym™ model and its application to hepatotoxicity testing in drug development
May 22, 2012
Dr. Toufigh Gordi, Rosa and Co.; President, PK/PD and Clinical Pharmacology Services
Mechanistic PK/PD Modeling in Pediatrics
Apr 17, 2012
Dr. Birgit Schoeberl; Vice President of Discovery; Merrimack Pharmaceuticals
Using mathematical models to set design criteria for antibody-based therapies
Mar 20, 2012
Joga Gobburu, PhD FCP MBA; School of Pharmacy|School of Medicine, Univ. of Maryland, Baltimore
Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions
Feb 13, 2012
Hartmut Derendorf, PhD; University of Florida, Gainesville
PK/PD-based Development of Anti-infective Agents
Dec 13, 2011
Tristan Maurer, PharmD, PhD; Research Fellow at Pfizer Pharmaceuticals
Translational Modeling & Simulation in Support of Rational Drug Discovery: Principles, Challenges and Examples
Nov 14, 2011
William J. Jusko, PhD, SUNY (Buffalo)
Moving PK/PD From Basic Towards Systems Pharmacology
Oct 17, 2011
Christina Friedrich, PhD, Rosa & Co
Developing Models that are Fit for Purpose — A Model Qualification Method
Sep 19, 2011
Nick Holford, MBChB, University of Auckland, New Zealand
Clinical Pharmacology = Disease Progression + Drug Action
Jul 26, 2011
Herbert Sauro, PhD, University of Washington, Seattle
Standards and Software in Biomedical Systems Modeling
Jun 20, 2011
Rebecca Baillie, PhD, Rosa & Co
How to build a PhysioPD model
May 24, 2011
Rada Savic, PhD, Uppsala University
Overview of modeling tools in drug development
Apr 18, 2011
Joga Gobburu, PhD, Division of Parmacometrics, OCP/FDA
Learn & Apply Paradigm in Drug Development: How disease-drug-trial models can aid decisions